Preclinical development of MGO Manuka Honey microemulsion for blepharitis management

ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysis...

Full description

Saved in:
Bibliographic Details
Published inBMJ open ophthalmology Vol. 1; no. 1; p. e000065
Main Authors Craig, Jennifer P, Rupenthal, Ilva D, Seyfoddin, Ali, Cheung, Isabella M Y, Uy, Benedict, Wang, Michael T M, Watters, Grant A, Swift, Simon
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.08.2017
BMJ Open Ophthalmology
Subjects
Online AccessGet full text
ISSN2397-3269
2397-3269
DOI10.1136/bmjophth-2016-000065

Cover

Loading…
Abstract ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysis In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.Results In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).ConclusionOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.
AbstractList ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysisIn vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined.In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.ResultsIn vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa.In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).ConclusionOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.
To evaluate the antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME). phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for , and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for and with cyclodextrin-complexed and uncomplexed Manuka honey were determined. phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation. phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both and , but not . phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05). Overall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.
To evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).OBJECTIVETo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.METHODS AND ANALYSISIn vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).RESULTSIn vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).Overall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.CONCLUSIONOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.
ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysis In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.Results In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).ConclusionOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.
Author Uy, Benedict
Cheung, Isabella M Y
Rupenthal, Ilva D
Craig, Jennifer P
Watters, Grant A
Swift, Simon
Seyfoddin, Ali
Wang, Michael T M
AuthorAffiliation 1 Department of Ophthalmology , New Zealand National Eye Centre, The University of Auckland , Auckland , New Zealand
2 Faculty of Health and Environmental Sciences , School of Science, AUT University , Auckland , New Zealand
3 Department of Molecular Medicine and Pathology , The University of Auckland , Auckland , New Zealand
AuthorAffiliation_xml – name: 3 Department of Molecular Medicine and Pathology , The University of Auckland , Auckland , New Zealand
– name: 1 Department of Ophthalmology , New Zealand National Eye Centre, The University of Auckland , Auckland , New Zealand
– name: 2 Faculty of Health and Environmental Sciences , School of Science, AUT University , Auckland , New Zealand
Author_xml – sequence: 1
  givenname: Jennifer P
  surname: Craig
  fullname: Craig, Jennifer P
  email: jp.craig@auckland.ac.nz
  organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
– sequence: 2
  givenname: Ilva D
  surname: Rupenthal
  fullname: Rupenthal, Ilva D
  email: jp.craig@auckland.ac.nz
  organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
– sequence: 3
  givenname: Ali
  surname: Seyfoddin
  fullname: Seyfoddin, Ali
  email: jp.craig@auckland.ac.nz
  organization: Faculty of Health and Environmental Sciences, School of Science, AUT University, Auckland, New Zealand
– sequence: 4
  givenname: Isabella M Y
  surname: Cheung
  fullname: Cheung, Isabella M Y
  email: jp.craig@auckland.ac.nz
  organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
– sequence: 5
  givenname: Benedict
  surname: Uy
  fullname: Uy, Benedict
  email: jp.craig@auckland.ac.nz
  organization: Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
– sequence: 6
  givenname: Michael T M
  surname: Wang
  fullname: Wang, Michael T M
  email: jp.craig@auckland.ac.nz
  organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
– sequence: 7
  givenname: Grant A
  surname: Watters
  fullname: Watters, Grant A
  email: jp.craig@auckland.ac.nz
  organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
– sequence: 8
  givenname: Simon
  surname: Swift
  fullname: Swift, Simon
  email: jp.craig@auckland.ac.nz
  organization: Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29354709$$D View this record in MEDLINE/PubMed
BookMark eNqNkU9LHTEUxUOxVKt-g1IC3XQzdTKZJJMuCiKtCoou7Drkry-vmWSazAh---bxfMW6sdkkcH_n3Jt73oO9mKIF4ANqvyCE6Yka12lazaumaxFt2nooeQMOOsxZgzvK956998FxKeuKII5o39F3YL_jmPSs5Qfg7jZbHXz0WgZo7IMNaRptnGFy8Pr8Bl7LuPyS8KK2f4Sj1znZcQnFpwhdylAFO61k9rMvcJRR3tuN-Ai8dTIUe_x0H4KfP77fnV00Vzfnl2enV43qGZ0bhAhv9eCw6ZwxcqCGSoaR7RXWg3FY6V5xx5Cmuh2kUUQ6ZChTVClJJFP4EHzb-k6LGq3RtXWWQUzZjzI_iiS9-LcS_UrcpwdBWIcoxtXg85NBTr8XW2Yx-qJtCDLatBSB-MA5IgT1Ff30Al2nJcf6PdFVgBFKUFupj88n-jvKbuEV-LoF6iZLydYJ7Wc5133WAX0QqBWbgMUuYLEJWGwDruL-hXjn_4rsZCur1f9T_AFAVL2N
CitedBy_id crossref_primary_10_1007_s00717_021_00497_3
crossref_primary_10_1136_bjophthalmol_2019_315160
crossref_primary_10_2147_OPTH_S440199
crossref_primary_10_1016_j_jtos_2017_05_006
crossref_primary_10_1515_biol_2025_1069
crossref_primary_10_3390_ph15111419
crossref_primary_10_3390_medicina60091458
crossref_primary_10_1016_j_jtos_2019_02_010
crossref_primary_10_3390_pharmaceutics14071493
crossref_primary_10_1016_j_clae_2018_06_006
crossref_primary_10_1016_j_jtos_2019_11_009
crossref_primary_10_1089_jop_2019_0135
Cites_doi 10.1097/OPX.0000000000000601
10.1097/01.ico.0000225716.85382.7b
10.1167/iovs.10-6997g
10.1093/jac/dkr340
10.1111/j.1444-0938.2001.tb04930.x
10.1111/j.1444-0938.2010.00540.x
10.1016/j.carres.2007.12.011
10.1097/01.ICL.0000095229.01957.89
10.1016/j.jtos.2016.03.002
10.1097/ICL.0000000000000124
10.1016/S1542-0124(12)70620-1
10.1096/fj.09-150789
10.1007/s10973-011-1406-z
10.1016/j.tim.2004.11.001
10.1007/s10096-010-1121-x
10.1097/ICO.0b013e3181bd4756
10.1167/iovs.10-6997a
10.1080/01676830600666185
10.1097/00003226-200310000-00008
10.1016/S1773-2247(11)50078-4
10.1615/CritRevTherDrugCarrierSyst.v14.i1.10
10.1097/00003226-199110010-00010
10.1136/bjo.68.8.524
10.1111/j.2042-7158.1991.tb03186.x
10.1016/j.jtos.2014.05.005
10.1016/S0308-8146(03)00258-9
10.1002/jps.23077
10.31989/ffhd.v4i5.13
10.1007/978-1-4615-5359-5_141
10.1016/S0580-9517(08)70474-4
10.1111/ceo.12810
10.1007/BF00656817
10.1167/iovs.12-9922
10.1007/978-1-4615-5359-5_121
ContentType Journal Article
Copyright Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
2016 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2016
Copyright_xml – notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
– notice: 2016 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2016
DBID 9YT
ACMMV
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1136/bmjophth-2016-000065
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Eastern Edition
PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2397-3269
ExternalDocumentID PMC5721633
29354709
10_1136_bmjophth_2016_000065
bmjophth
Genre Journal Article
GeographicLocations New Zealand
United States--US
GeographicLocations_xml – name: United States--US
– name: New Zealand
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
7X7
8FI
8FJ
9YT
ABUWG
ACGFS
ACMMV
ADBBV
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
BENPR
BTFSW
CCPQU
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
M~E
O9-
OK1
RHI
RMJ
RPM
UKHRP
AAYXX
CITATION
NPM
RHF
3V.
7XB
8FK
K9.
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-b476t-11590c8f3d2fdda86d6a731e4b3c8df3bc4b9f71c6c08adb5af1d67b6bba5a7b3
IEDL.DBID 9YT
ISSN 2397-3269
IngestDate Thu Aug 21 14:13:05 EDT 2025
Fri Jul 11 16:15:34 EDT 2025
Mon Jun 30 04:12:03 EDT 2025
Thu Jan 02 22:55:07 EST 2025
Wed Sep 03 16:44:52 EDT 2025
Thu Apr 24 23:03:07 EDT 2025
Thu Apr 24 23:05:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords methylglyoxal
Blepharitis
Manuka honey
cyclodextrin
Language English
License This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b476t-11590c8f3d2fdda86d6a731e4b3c8df3bc4b9f71c6c08adb5af1d67b6bba5a7b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://dx.doi.org/10.1136/bmjophth-2016-000065
PMID 29354709
PQID 2551756510
PQPubID 5161127
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5721633
proquest_miscellaneous_1989915514
proquest_journals_2551756510
pubmed_primary_29354709
crossref_citationtrail_10_1136_bmjophth_2016_000065
crossref_primary_10_1136_bmjophth_2016_000065
bmj_primary_10_1136_bmjophth_2016_000065
PublicationCentury 2000
PublicationDate 2017-08-01
PublicationDateYYYYMMDD 2017-08-01
PublicationDate_xml – month: 08
  year: 2017
  text: 2017-08-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationTitle BMJ open ophthalmology
PublicationTitleAlternate BMJ Open Ophthalmol
PublicationYear 2017
Publisher BMJ Publishing Group LTD
BMJ Open Ophthalmology
Publisher_xml – name: BMJ Publishing Group LTD
– name: BMJ Open Ophthalmology
References Dougherty, McCulley 1986; 27
Thompson 1997; 14
Swift, Chepulis, Uy 2014; 4
Jenkins, Burton, Cooper 2011; 66
Fux, Shirtliff, Stoodley 2005; 13
Albietz 2001; 84
Geerling, Tauber, Baudouin 2011; 52
Wang, Jaitley, Lord 2015; 92
MacKeen, Roth, Doane 1998; 438
Habib, El-Mahdy, Maher 2011; 21
Lemp, Nichols 2009; 7
Guillon 1998; 438
Romero, Biser, Perry 2004; 30
Mukherjee, Chaki, Das 2011; 49
Adams, Boult, Deadman 2008; 343
Dougherty, McCulley 1984; 68
Groden, Murphy, Rodnite 1991; 10
Snow, Manley-Harris 2004; 84
Bron, Evans, Smith 2003; 22
Albietz, Lenton 2006; 25
Nichols, Foulks, Bron 2011; 52
Allen, Molan, Reid 1991; 43
Chadha, Arora, Gupta 2011; 105
Hughes, Ahmed, Hammond 2007; 26
Goto, Zheng, Gibbon 2010; 29
Á, Szejtli, Barcza 1983; 1
Lee, DH, Jung 2012; 53
Opitz, Tyler 2011; 94
Pflugfelder, Karpecki, Perez 2014; 12
Lindsley, Matsumura, Hatef 2012; 5
Loftsson, Brewster 2012; 101
Lin, Molan, Cursons 2011; 30
Watters, Turnbull, Swift 2017; 45
Schleifer, Kandler 1972; 36
Ng, Evans, North 2015; 41
Craig, Wang, Kim 2016; 14
Kwakman, te Velde, de Boer 2010; 24
2025090109161508000_1.1.e000065.5
2025090109161508000_1.1.e000065.4
Craig (2025090109161508000_1.1.e000065.23) 2016; 14
Pflugfelder (2025090109161508000_1.1.e000065.9) 2014; 12
2025090109161508000_1.1.e000065.3
2025090109161508000_1.1.e000065.2
Watters (2025090109161508000_1.1.e000065.6) 2017; 45
Guillon (2025090109161508000_1.1.e000065.22) 1998; 438
Albietz (2025090109161508000_1.1.e000065.13) 2001; 84
Habib (2025090109161508000_1.1.e000065.32) 2011; 21
Chadha (2025090109161508000_1.1.e000065.34) 2011; 105
2025090109161508000_1.1.e000065.21
Mukherjee (2025090109161508000_1.1.e000065.29) 2011; 49
Swift (2025090109161508000_1.1.e000065.20) 2014; 4
Thompson (2025090109161508000_1.1.e000065.19) 1997; 14
Dougherty (2025090109161508000_1.1.e000065.10) 1986; 27
2025090109161508000_1.1.e000065.28
2025090109161508000_1.1.e000065.27
2025090109161508000_1.1.e000065.26
2025090109161508000_1.1.e000065.25
2025090109161508000_1.1.e000065.24
Ng (2025090109161508000_1.1.e000065.35) 2015; 41
Goto (2025090109161508000_1.1.e000065.37) 2010; 29
Lindsley (2025090109161508000_1.1.e000065.1) 2012; 5
MacKeen (2025090109161508000_1.1.e000065.36) 1998; 438
Lin (2025090109161508000_1.1.e000065.30) 2011; 30
Groden (2025090109161508000_1.1.e000065.8) 1991; 10
2025090109161508000_1.1.e000065.31
Hughes (2025090109161508000_1.1.e000065.7) 2007; 26
Á (2025090109161508000_1.1.e000065.33) 1983; 1
2025090109161508000_1.1.e000065.18
2025090109161508000_1.1.e000065.17
Wang (2025090109161508000_1.1.e000065.15) 2015; 92
2025090109161508000_1.1.e000065.16
2025090109161508000_1.1.e000065.14
2025090109161508000_1.1.e000065.12
2025090109161508000_1.1.e000065.11
References_xml – volume: 92
  start-page: e321
  year: 2015
  article-title: Comparison of Self-applied Heat Therapy for Meibomian Gland Dysfunction
  publication-title: Optom Vis Sci
  doi: 10.1097/OPX.0000000000000601
– volume: 25
  start-page: 1012
  year: 2006
  article-title: Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease
  publication-title: Cornea
  doi: 10.1097/01.ico.0000225716.85382.7b
– volume: 52
  start-page: 2050
  year: 2011
  article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997g
– volume: 66
  start-page: 2536
  year: 2011
  article-title: Manuka honey inhibits cell division in methicillin-resistant Staphylococcus aureus
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr340
– volume: 84
  start-page: 4
  year: 2001
  article-title: Dry eye: an update on clinical diagnosis, management and promising new treatments
  publication-title: Clin Exp Optom
  doi: 10.1111/j.1444-0938.2001.tb04930.x
– volume: 94
  start-page: 200
  year: 2011
  article-title: Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis
  publication-title: Clin Exp Optom
  doi: 10.1111/j.1444-0938.2010.00540.x
– volume: 36
  start-page: 407
  year: 1972
  article-title: Peptidoglycan types of bacterial cell walls and their taxonomic implications
  publication-title: Bacteriol Rev
– volume: 343
  start-page: 651
  year: 2008
  article-title: Isolation by HPLC and characterisation of the bioactive fraction of New Zealand manuka (Leptospermum scoparium) honey
  publication-title: Carbohydr Res
  doi: 10.1016/j.carres.2007.12.011
– volume: 53
  start-page: 5585
  year: 2012
  article-title: Comparative Ocular Microbial Communities in Humans with and without BlepharitisOcular Microbial Communities
  publication-title: Investigative ophthalmology & visual science
– volume: 30
  start-page: 14
  year: 2004
  article-title: Conservative treatment of meibomian gland dysfunction
  publication-title: Eye Contact Lens
  doi: 10.1097/01.ICL.0000095229.01957.89
– volume: 14
  start-page: 385
  year: 2016
  article-title: Exploring the Predisposition of the Asian Eye to Development of Dry Eye
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2016.03.002
– volume: 41
  start-page: 304
  year: 2015
  article-title: Migration of Cosmetic Products into the Tear Film
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000124
– volume: 7
  start-page: S1
  year: 2009
  article-title: Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment
  publication-title: Ocul Surf
  doi: 10.1016/S1542-0124(12)70620-1
– volume: 24
  start-page: 2576
  year: 2010
  article-title: How honey kills bacteria
  publication-title: FASEB J
  doi: 10.1096/fj.09-150789
– volume: 105
  start-page: 1049
  year: 2011
  article-title: Complexation of nevirapine with β-cyclodextrins in the presence and absence of Tween 80: characterization, thermodynamic parameters, and permeability flux
  publication-title: J Therm Anal Calorim
  doi: 10.1007/s10973-011-1406-z
– volume: 27
  start-page: 486
  year: 1986
  article-title: Bacterial lipases and chronic blepharitis
  publication-title: Invest Ophthalmol Vis Sci
– volume: 45
  start-page: 105
  year: 2017
  article-title: Ocular surface microbiome in meibomian gland dysfunction in Auckland, New Zealand
  publication-title: Clin Exp Ophthalmol
– volume: 4
  start-page: 172
  year: 2014
  article-title: Enhanced Antibacterial Activity of MGOTM Manuka Honey complexed with a-cyclodextrin (Manuka Honey with CycloPowerTM)
  publication-title: Functional Foods in Health and Disease
– volume: 13
  start-page: 58
  year: 2005
  article-title: Can laboratory reference strains mirror "real-world" pathogenesis?
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2004.11.001
– volume: 30
  start-page: 569
  year: 2011
  article-title: The controlled in vitro susceptibility of gastrointestinal pathogens to the antibacterial effect of manuka honey
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/s10096-010-1121-x
– volume: 1
  start-page: 151
  year: 1983
  article-title: Complexes of short-chain alcohols with β-cyclodextrin
  publication-title: Journal of inclusion phenomena
– volume: 438
  start-page: 859
  year: 1998
  article-title: Use of the Tearscope Plus and attachments in the routine examination of the marginal dry eye contact lens patient
  publication-title: Adv Exp Med Biol
– volume: 29
  start-page: 400
  year: 2010
  article-title: Cosmetic product migration onto the ocular surface: exacerbation of migration after eyedrop instillation
  publication-title: Cornea
  doi: 10.1097/ICO.0b013e3181bd4756
– volume: 52
  start-page: 1922
  year: 2011
  article-title: The international workshop on meibomian gland dysfunction: executive summary
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997a
– volume: 26
  start-page: 47
  year: 2007
  article-title: Necrotizing pseudomonas blepharoconjunctivitis
  publication-title: Orbit
  doi: 10.1080/01676830600666185
– volume: 22
  start-page: 640
  year: 2003
  article-title: Grading of corneal and conjunctival staining in the context of other dry eye tests
  publication-title: Cornea
  doi: 10.1097/00003226-200310000-00008
– volume: 21
  start-page: 485
  year: 2011
  article-title: Microemulsions for ocular delivery: evaluation and characterization
  publication-title: J Drug Deliv Sci Technol
  doi: 10.1016/S1773-2247(11)50078-4
– volume: 14
  start-page: 1
  year: 1997
  article-title: Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals
  publication-title: Crit Rev Ther Drug Carrier Syst
  doi: 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10
– volume: 5
  year: 2012
  article-title: Interventions for chronic blepharitis
  publication-title: Cochrane Database Syst Rev
– volume: 10
  start-page: 50
  year: 1991
  article-title: Lid flora in blepharitis
  publication-title: Cornea
  doi: 10.1097/00003226-199110010-00010
– volume: 68
  start-page: 524
  year: 1984
  article-title: Comparative bacteriology of chronic blepharitis
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.68.8.524
– volume: 43
  start-page: 817
  year: 1991
  article-title: A survey of the antibacterial activity of some New Zealand honeys
  publication-title: J Pharm Pharmacol
  doi: 10.1111/j.2042-7158.1991.tb03186.x
– volume: 49
  start-page: 547
  year: 2011
  article-title: Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa
  publication-title: Indian J Exp Biol
– volume: 438
  start-page: 985
  year: 1998
  article-title: Supracutaneous treatment of dry eye patients with calcium carbonate
  publication-title: Adv Exp Med Biol
– volume: 12
  start-page: 273
  year: 2014
  article-title: Treatment of blepharitis: recent clinical trials
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2014.05.005
– volume: 84
  start-page: 145
  year: 2004
  article-title: On the nature of non-peroxide antibacterial activity in New Zealand manuka honey
  publication-title: Food Chem
  doi: 10.1016/S0308-8146(03)00258-9
– volume: 101
  start-page: 3019
  year: 2012
  article-title: Cyclodextrins as functional excipients: methods to enhance complexation efficiency
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23077
– volume: 4
  start-page: 172
  year: 2014
  ident: 2025090109161508000_1.1.e000065.20
  article-title: Enhanced Antibacterial Activity of MGOTM Manuka Honey complexed with a-cyclodextrin (Manuka Honey with CycloPowerTM)
  publication-title: Functional Foods in Health and Disease
  doi: 10.31989/ffhd.v4i5.13
– ident: 2025090109161508000_1.1.e000065.25
  doi: 10.1016/j.carres.2007.12.011
– volume: 12
  start-page: 273
  year: 2014
  ident: 2025090109161508000_1.1.e000065.9
  article-title: Treatment of blepharitis: recent clinical trials
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2014.05.005
– ident: 2025090109161508000_1.1.e000065.14
  doi: 10.1097/01.ICL.0000095229.01957.89
– volume: 84
  start-page: 4
  year: 2001
  ident: 2025090109161508000_1.1.e000065.13
  article-title: Dry eye: an update on clinical diagnosis, management and promising new treatments
  publication-title: Clin Exp Optom
  doi: 10.1111/j.1444-0938.2001.tb04930.x
– ident: 2025090109161508000_1.1.e000065.28
  doi: 10.1096/fj.09-150789
– ident: 2025090109161508000_1.1.e000065.12
  doi: 10.1111/j.1444-0938.2010.00540.x
– ident: 2025090109161508000_1.1.e000065.24
  doi: 10.1097/00003226-200310000-00008
– ident: 2025090109161508000_1.1.e000065.5
  doi: 10.1136/bjo.68.8.524
– volume: 105
  start-page: 1049
  year: 2011
  ident: 2025090109161508000_1.1.e000065.34
  article-title: Complexation of nevirapine with β-cyclodextrins in the presence and absence of Tween 80: characterization, thermodynamic parameters, and permeability flux
  publication-title: J Therm Anal Calorim
  doi: 10.1007/s10973-011-1406-z
– volume: 438
  start-page: 985
  year: 1998
  ident: 2025090109161508000_1.1.e000065.36
  article-title: Supracutaneous treatment of dry eye patients with calcium carbonate
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-5359-5_141
– volume: 14
  start-page: 1
  year: 1997
  ident: 2025090109161508000_1.1.e000065.19
  article-title: Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals
  publication-title: Crit Rev Ther Drug Carrier Syst
  doi: 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10
– volume: 26
  start-page: 47
  year: 2007
  ident: 2025090109161508000_1.1.e000065.7
  article-title: Necrotizing pseudomonas blepharoconjunctivitis
  publication-title: Orbit
  doi: 10.1080/01676830600666185
– volume: 49
  start-page: 547
  year: 2011
  ident: 2025090109161508000_1.1.e000065.29
  article-title: Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa
  publication-title: Indian J Exp Biol
– volume: 21
  start-page: 485
  year: 2011
  ident: 2025090109161508000_1.1.e000065.32
  article-title: Microemulsions for ocular delivery: evaluation and characterization
  publication-title: J Drug Deliv Sci Technol
  doi: 10.1016/S1773-2247(11)50078-4
– volume: 14
  start-page: 385
  year: 2016
  ident: 2025090109161508000_1.1.e000065.23
  article-title: Exploring the Predisposition of the Asian Eye to Development of Dry Eye
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2016.03.002
– ident: 2025090109161508000_1.1.e000065.21
  doi: 10.1111/j.2042-7158.1991.tb03186.x
– ident: 2025090109161508000_1.1.e000065.31
  doi: 10.1016/j.tim.2004.11.001
– ident: 2025090109161508000_1.1.e000065.26
  doi: 10.1093/jac/dkr340
– volume: 27
  start-page: 486
  year: 1986
  ident: 2025090109161508000_1.1.e000065.10
  article-title: Bacterial lipases and chronic blepharitis
  publication-title: Invest Ophthalmol Vis Sci
– ident: 2025090109161508000_1.1.e000065.3
  doi: 10.1167/iovs.10-6997a
– ident: 2025090109161508000_1.1.e000065.11
  doi: 10.1167/iovs.10-6997g
– ident: 2025090109161508000_1.1.e000065.18
  doi: 10.1002/jps.23077
– volume: 92
  start-page: e321
  year: 2015
  ident: 2025090109161508000_1.1.e000065.15
  article-title: Comparison of Self-applied Heat Therapy for Meibomian Gland Dysfunction
  publication-title: Optom Vis Sci
  doi: 10.1097/OPX.0000000000000601
– volume: 30
  start-page: 569
  year: 2011
  ident: 2025090109161508000_1.1.e000065.30
  article-title: The controlled in vitro susceptibility of gastrointestinal pathogens to the antibacterial effect of manuka honey
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/s10096-010-1121-x
– ident: 2025090109161508000_1.1.e000065.27
  doi: 10.1016/S0580-9517(08)70474-4
– volume: 29
  start-page: 400
  year: 2010
  ident: 2025090109161508000_1.1.e000065.37
  article-title: Cosmetic product migration onto the ocular surface: exacerbation of migration after eyedrop instillation
  publication-title: Cornea
  doi: 10.1097/ICO.0b013e3181bd4756
– ident: 2025090109161508000_1.1.e000065.17
  doi: 10.1016/S0308-8146(03)00258-9
– volume: 5
  year: 2012
  ident: 2025090109161508000_1.1.e000065.1
  article-title: Interventions for chronic blepharitis
  publication-title: Cochrane Database Syst Rev
– ident: 2025090109161508000_1.1.e000065.2
  doi: 10.1016/S1542-0124(12)70620-1
– volume: 10
  start-page: 50
  year: 1991
  ident: 2025090109161508000_1.1.e000065.8
  article-title: Lid flora in blepharitis
  publication-title: Cornea
  doi: 10.1097/00003226-199110010-00010
– volume: 41
  start-page: 304
  year: 2015
  ident: 2025090109161508000_1.1.e000065.35
  article-title: Migration of Cosmetic Products into the Tear Film
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000124
– volume: 45
  start-page: 105
  year: 2017
  ident: 2025090109161508000_1.1.e000065.6
  article-title: Ocular surface microbiome in meibomian gland dysfunction in Auckland, New Zealand
  publication-title: Clin Exp Ophthalmol
  doi: 10.1111/ceo.12810
– ident: 2025090109161508000_1.1.e000065.16
  doi: 10.1097/01.ico.0000225716.85382.7b
– volume: 1
  start-page: 151
  year: 1983
  ident: 2025090109161508000_1.1.e000065.33
  article-title: Complexes of short-chain alcohols with β-cyclodextrin
  publication-title: Journal of inclusion phenomena
  doi: 10.1007/BF00656817
– ident: 2025090109161508000_1.1.e000065.4
  doi: 10.1167/iovs.12-9922
– volume: 438
  start-page: 859
  year: 1998
  ident: 2025090109161508000_1.1.e000065.22
  article-title: Use of the Tearscope Plus and attachments in the routine examination of the marginal dry eye contact lens patient
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-5359-5_121
SSID ssj0001916426
Score 2.0821202
Snippet ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with...
To evaluate the antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and rabbit eye...
To evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in...
SourceID pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e000065
SubjectTerms Antibiotics
Bacteria
Drug resistance
Honey
Inflammation
Laboratories
Microemulsions
Original
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELbGkBAvCNiAwEBG4mEv0erYsZMnhNBGhdTBwyb1zfKvqLA2KbR94L_nznHTdUjAaxzL1vl89_n8-Y6Qd8wrCyjcgfWrRC4qC3ZQcpl7Xklw-CGomPFmcinH1-LztJymgNsq0Sq3NjEaat85jJGfAfQFTydBhd4vf-RYNQpvV1MJjXvkPqYuQ0qXmqpdjAWwjyj6-nI17KVC1un1HOPyzC6-d8vZegaKwmQeDTd6GPi876P-AJ53-ZO3HNLFY_IoIUn6oV_6J-QgtE_Jg0m6Kz8iV1_BmKV3j9TvuEG0a-jk0xc6Me3mxtBx14ZfdIG8vLDYzDF4RgHIUjsPy5mJKY_oYuDIHJPri_Orj-M81VDIrVBynQPgq0euargvGu9NJb00irMgLHeVb7h1wtaNYk66UWW8LU3DvFRWWmtKoyx_Rg5bmMgLQn3NDR5_rKiNKFhT4Q_MAz4IjWDBZeQUZKeXfZYMHU8XXOqtmDWKWfdizgjfCli7lIscS2LM_9ErH3r93ygn27XTaWeu9E6PMvJ2aIY9hRclpg3dZqWRR1ZHLJmR5_1SDwMCPCqFGtUZUXtKMPyA-br3W9pvs5i3u8RESZy__Pu0XpGHBUKHSDI8IYfrn5vwGoDP2r6J2v0bGrYB3Q
  priority: 102
  providerName: ProQuest
Title Preclinical development of MGO Manuka Honey microemulsion for blepharitis management
URI http://bmjophth.bmj.com/content/1/1/e000065.full
https://www.ncbi.nlm.nih.gov/pubmed/29354709
https://www.proquest.com/docview/2551756510
https://www.proquest.com/docview/1989915514
https://pubmed.ncbi.nlm.nih.gov/PMC5721633
Volume 1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swED8NkNBeEGxshI_Kk_awl2h17djJIyCgmhSGpoLKk2XHjrrRphW0D_z3nN00pSA0niL5Q47u7Lvf2eefAb5TKw2i8AKtX8pjnhq0g4KJ2LJUoMN3TgbGm_xSdK_5r37SXwaKL07wKRM_zejfeDKYDlCfVMTBviZrsBFoWfyMvu0t91QQ66DHqW_IvdUZvQgWr_qhV-DyZY7kM6dzvg1bNVokx3P17sAHV32Czbw-D_8MvSs0WPXdRmKX-T9kXJL84jfJdTW706Q7rtwjGfncOzeaDf0GGUGwSszQTQY60BqRUZMHswvX52e9025cv5MQGy7FNEZQl7WLtGS2U1qrU2GFlow6bliR2pKZgpuslLQQRTvV1iS6pFZII4zRiZaGfYH1Cn9kD4jNmPYhjuGZ5h1apr4BtYgBXMmpKyL4gbJTkzkThgoRBBNqIWblxazmYo6ALQSsippv3D97MfxPr7jp9b5RDhe6U_Xqe1AYJiEqEmhuIvjWVOO68YchunLj2YPyuWJZwIsRfJ2ruhkQIVDCZTuLQK5MgqaB5-Reran-DgI3d-LJkBjbf7-cDuBjx0OFkFR4COvT-5k7QqAzNS1Yk33ZCnO8BRvHp3l-g9-Ts8urP62wefAEW6H_tg
linkProvider BMJ Publishing Group Ltd
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJe0PgODDASSLxEq2PHSR7QxMdGx5YyoU7am2fHjgq0SaGtpv1T-xs556sUJOBlr7EdW-fz3e_O5zuAF9REGlF4htIv5j6PNcpBwYRvWCxQ4VsbVRlv0qEYnPCPp-HpBly2b2FcWGUrEytBbcrM-ch3EPqiphPIQruz776rGuVuV9sSGjVbHNqLczTZ5q8P3uP-vgyC_b3Ru4HfVBXwNY_EwkcIlPSzOGcmyI1RsTBCRYxarlkWm5zpjOskj2gmsn6sjA5VTo2ItNBahSrSDP97DTY5Q1OmB5tv94bHn1deHURbPKgr2iV4egORNO_1KBM7evq1nI0XY2RNKvxKVTidhp_XteIfUPf3iM1fVOD-FtxqsCt5UzPbbdiwxR24nja383dhdIzis3lpScwqGomUOUk_fCKpKpbfFBmUhb0gUxcJaKfLiXPXEYTORE_sbKyqJEtk2kXl3IOTK6HvfegVuJCHQEzClDO4NE8UD2geuw7UICKxOac28-AV0k7O6rwcsrJnmJAtmaUjs6zJ7AFrCSyzJvu5K8Ix-ccovxv1f7Nst3snG1kwlyvO9eB514yn2F3NqMKWy7l0kWtJhV49eFBvdTchArKQR_3Eg2iNCboOLkP4ekvxZVxlCg9daibGHv19Wc_gxmCUHsmjg-HhY7gZOOBShThuQ2_xY2mfIOxa6KcNrxM4u-rj9RNYv0LU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4aQ5p4QdwXtoGRQOIlah07dvKA0MQoHaNjD5vUN2PHjgq0SVlbof01fh3HuZWCBLzsNY7j6PhcPtufzwF4Tq00iMIz9H4JD3li0A8KJkLLEoEB3zlZZbwZnYrhBX8_jsdb8KO9C-Npla1PrBy1LTO_R95D6IuRTqAK9fKGFnF2NHg9_xb6ClL-pLUtp1GryIm7-o7Lt8Wr4yOc6xdRNHh7_mYYNhUGQsOlWIYIh9J-luTMRrm1OhFWaMmo44Zlic2ZybhJc0kzkfUTbU2sc2qFNMIYHWtpGH73BtyULKbexuRYrvd3EHfxqK5tl6IdRyJtbu5RJnpm9qWcT5YTVFIqwipo-OiGjzfj4x-g93fu5i_BcHAHbjcolhzWancXtlxxD3ZGzTn9fTg_Q0fa3Lkkds1LImVORu8-kpEuVl81GZaFuyIzzwl0s9XUb9wRBNHETN18oqt0S2TW8XMewMW1SPchbBf4I7tAbMq0X3oZnmoe0TzxL1CL2MTlnLosgJcoOzWvM3SoamXDhGrFrLyYVS3mAFgrYJU1edB9OY7pP3qFXa__G2W_nTvVeIWFWutwAM-6ZrRnf0ijC1euFspz2NIKxwbwqJ7qbkCEZjGX_TQAuaEE3Qs-V_hmS_F5UuUMj32SJsYe__23nsIOGpX6cHx6sge3Io9gKq7jPmwvL1fuAPHX0jypFJ3Ap-u2rJ-koUWk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+development+of+MGO+Manuka+Honey+microemulsion+for+blepharitis+management&rft.jtitle=BMJ+open+ophthalmology&rft.au=Craig%2C+Jennifer+P&rft.au=Rupenthal%2C+Ilva+D&rft.au=Seyfoddin%2C+Ali&rft.au=Cheung%2C+Isabella+M+Y&rft.date=2017-08-01&rft.eissn=2397-3269&rft.volume=1&rft.issue=1&rft_id=info:doi/10.1136%2Fbmjophth-2016-000065&rft.externalDBID=bmjophth&rft.externalDocID=bmjophth
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2397-3269&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2397-3269&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2397-3269&client=summon